Audit: Annual mammographic surveillance for patients with moderate and high risk of family history of breast cancer. Is there scope for improvement?
Association of Breast Surgery ePoster Library. Pronisceva V. 05/15/17; 166261; P064
Ms. Veronika Pronisceva
REGULAR CONTENT
Login now to access Regular content available to all registered users.
Abstract
Rate & Comment (0)
Introduction: NICE recommendations are to offer annual mammographic surveillance between the ages 40-49 for women with moderate risk and between ages 40 to 59 for women with high risk of developing breast cancer.
Aim: To determine the incidence of early breast cancer in the patients who were recalled from 01/2015 to 12/2015 and the time taken from mammogram to completed assessment.
Standard: NICE CG164” Familial breast cancer: Mammographic surveillance.”
Method: Retrospective data collection. Patients with BRCA gene defect and PT53 mutation excluded.
Results: Currently we have 596 patients who undergo annual mammographic surveillance. 362(61%) patients with moderate and 243(39%) with high risk. 64(100%) patients from annual mammographic surveillance were recalled for further imaging and examination between 1/2015-12/2015. 34(53%) patients were high risk and 30(47%) moderate risk. Of the 64 recalled patients, 6(9%) resulted in a biopsy,1(1.6%)patient had B3 biopsy results, 2(3%) patients B2 -fibroadenoma, 1(1.6%) had silicon node, 2(3%) patients had new diagnosis of early cancer (1 high risk, 1 intermediate risk). Median waiting time from date of original mammogram to completeness of the assessment was 19 days with range 4-44.
Conclusion: In our experience patients with high and moderate risk of breast cancer due to family history have a 9%chance of being offered a biopsy following recall mammogram and 3% chance of a of early breast cancer. Waiting time for final imaging and biopsy results has a large variation due to difference in pathway of recall. It highlighted a need for a streamlined pathway equivalent to NHSBP standards.
Aim: To determine the incidence of early breast cancer in the patients who were recalled from 01/2015 to 12/2015 and the time taken from mammogram to completed assessment.
Standard: NICE CG164” Familial breast cancer: Mammographic surveillance.”
Method: Retrospective data collection. Patients with BRCA gene defect and PT53 mutation excluded.
Results: Currently we have 596 patients who undergo annual mammographic surveillance. 362(61%) patients with moderate and 243(39%) with high risk. 64(100%) patients from annual mammographic surveillance were recalled for further imaging and examination between 1/2015-12/2015. 34(53%) patients were high risk and 30(47%) moderate risk. Of the 64 recalled patients, 6(9%) resulted in a biopsy,1(1.6%)patient had B3 biopsy results, 2(3%) patients B2 -fibroadenoma, 1(1.6%) had silicon node, 2(3%) patients had new diagnosis of early cancer (1 high risk, 1 intermediate risk). Median waiting time from date of original mammogram to completeness of the assessment was 19 days with range 4-44.
Conclusion: In our experience patients with high and moderate risk of breast cancer due to family history have a 9%chance of being offered a biopsy following recall mammogram and 3% chance of a of early breast cancer. Waiting time for final imaging and biopsy results has a large variation due to difference in pathway of recall. It highlighted a need for a streamlined pathway equivalent to NHSBP standards.
Introduction: NICE recommendations are to offer annual mammographic surveillance between the ages 40-49 for women with moderate risk and between ages 40 to 59 for women with high risk of developing breast cancer.
Aim: To determine the incidence of early breast cancer in the patients who were recalled from 01/2015 to 12/2015 and the time taken from mammogram to completed assessment.
Standard: NICE CG164” Familial breast cancer: Mammographic surveillance.”
Method: Retrospective data collection. Patients with BRCA gene defect and PT53 mutation excluded.
Results: Currently we have 596 patients who undergo annual mammographic surveillance. 362(61%) patients with moderate and 243(39%) with high risk. 64(100%) patients from annual mammographic surveillance were recalled for further imaging and examination between 1/2015-12/2015. 34(53%) patients were high risk and 30(47%) moderate risk. Of the 64 recalled patients, 6(9%) resulted in a biopsy,1(1.6%)patient had B3 biopsy results, 2(3%) patients B2 -fibroadenoma, 1(1.6%) had silicon node, 2(3%) patients had new diagnosis of early cancer (1 high risk, 1 intermediate risk). Median waiting time from date of original mammogram to completeness of the assessment was 19 days with range 4-44.
Conclusion: In our experience patients with high and moderate risk of breast cancer due to family history have a 9%chance of being offered a biopsy following recall mammogram and 3% chance of a of early breast cancer. Waiting time for final imaging and biopsy results has a large variation due to difference in pathway of recall. It highlighted a need for a streamlined pathway equivalent to NHSBP standards.
Aim: To determine the incidence of early breast cancer in the patients who were recalled from 01/2015 to 12/2015 and the time taken from mammogram to completed assessment.
Standard: NICE CG164” Familial breast cancer: Mammographic surveillance.”
Method: Retrospective data collection. Patients with BRCA gene defect and PT53 mutation excluded.
Results: Currently we have 596 patients who undergo annual mammographic surveillance. 362(61%) patients with moderate and 243(39%) with high risk. 64(100%) patients from annual mammographic surveillance were recalled for further imaging and examination between 1/2015-12/2015. 34(53%) patients were high risk and 30(47%) moderate risk. Of the 64 recalled patients, 6(9%) resulted in a biopsy,1(1.6%)patient had B3 biopsy results, 2(3%) patients B2 -fibroadenoma, 1(1.6%) had silicon node, 2(3%) patients had new diagnosis of early cancer (1 high risk, 1 intermediate risk). Median waiting time from date of original mammogram to completeness of the assessment was 19 days with range 4-44.
Conclusion: In our experience patients with high and moderate risk of breast cancer due to family history have a 9%chance of being offered a biopsy following recall mammogram and 3% chance of a of early breast cancer. Waiting time for final imaging and biopsy results has a large variation due to difference in pathway of recall. It highlighted a need for a streamlined pathway equivalent to NHSBP standards.
Code of conduct/disclaimer available in General Terms & Conditions
{{ help_message }}
{{filter}}